Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294012503> ?p ?o ?g. }
- W4294012503 endingPage "1652" @default.
- W4294012503 startingPage "1638" @default.
- W4294012503 abstract "Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are currently under clinical development for treating anemia in chronic kidney disease (CKD), but it is important to monitor their cardiovascular safety. Genetic variants can be used as predictors to help inform the potential risk of adverse effects associated with drug treatments. We therefore aimed to use human genetics to help assess the risk of adverse cardiovascular events associated with therapeutically altered EPO levels to help inform clinical trials studying the safety of HIF-PHIs. By performing a genome-wide association meta-analysis of EPO (n = 6,127), we identified a cis-EPO variant (rs1617640) lying in the EPO promoter region. We validated this variant as most likely causal in controlling EPO levels by using genetic and functional approaches, including single-base gene editing. Using this variant as a partial predictor for therapeutic modulation of EPO and large genome-wide association data in Mendelian randomization tests, we found no evidence (at p < 0.05) that genetically predicted long-term rises in endogenous EPO, equivalent to a 2.2-unit increase, increased risk of coronary artery disease (CAD, OR [95% CI] = 1.01 [0.93, 1.07]), myocardial infarction (MI, OR [95% CI] = 0.99 [0.87, 1.15]), or stroke (OR [95% CI] = 0.97 [0.87, 1.07]). We could exclude increased odds of 1.15 for cardiovascular disease for a 2.2-unit EPO increase. A combination of genetic and functional studies provides a powerful approach to investigate the potential therapeutic profile of EPO-increasing therapies for treating anemia in CKD." @default.
- W4294012503 created "2022-09-01" @default.
- W4294012503 creator A5002396490 @default.
- W4294012503 creator A5005549802 @default.
- W4294012503 creator A5005555807 @default.
- W4294012503 creator A5006065540 @default.
- W4294012503 creator A5012221988 @default.
- W4294012503 creator A5015864662 @default.
- W4294012503 creator A5016238665 @default.
- W4294012503 creator A5016744557 @default.
- W4294012503 creator A5017233964 @default.
- W4294012503 creator A5018149893 @default.
- W4294012503 creator A5021552171 @default.
- W4294012503 creator A5025710476 @default.
- W4294012503 creator A5027172687 @default.
- W4294012503 creator A5027394675 @default.
- W4294012503 creator A5027571680 @default.
- W4294012503 creator A5033284534 @default.
- W4294012503 creator A5034839238 @default.
- W4294012503 creator A5037600662 @default.
- W4294012503 creator A5038242626 @default.
- W4294012503 creator A5041676520 @default.
- W4294012503 creator A5044048234 @default.
- W4294012503 creator A5044144962 @default.
- W4294012503 creator A5045774368 @default.
- W4294012503 creator A5046230847 @default.
- W4294012503 creator A5048196698 @default.
- W4294012503 creator A5049763932 @default.
- W4294012503 creator A5056293127 @default.
- W4294012503 creator A5060580344 @default.
- W4294012503 creator A5076542409 @default.
- W4294012503 creator A5079276216 @default.
- W4294012503 creator A5080274332 @default.
- W4294012503 creator A5090671996 @default.
- W4294012503 creator A5091741059 @default.
- W4294012503 date "2022-09-01" @default.
- W4294012503 modified "2023-10-14" @default.
- W4294012503 title "Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies" @default.
- W4294012503 cites W1595237219 @default.
- W4294012503 cites W1696199194 @default.
- W4294012503 cites W1707428129 @default.
- W4294012503 cites W1966775465 @default.
- W4294012503 cites W1980168725 @default.
- W4294012503 cites W1984393349 @default.
- W4294012503 cites W1986436077 @default.
- W4294012503 cites W1992911777 @default.
- W4294012503 cites W1998943227 @default.
- W4294012503 cites W2020104306 @default.
- W4294012503 cites W2033151532 @default.
- W4294012503 cites W2033380296 @default.
- W4294012503 cites W2033803279 @default.
- W4294012503 cites W2036897871 @default.
- W4294012503 cites W2044692611 @default.
- W4294012503 cites W2053551121 @default.
- W4294012503 cites W2070050178 @default.
- W4294012503 cites W2073836327 @default.
- W4294012503 cites W2080225144 @default.
- W4294012503 cites W2080268715 @default.
- W4294012503 cites W2081970575 @default.
- W4294012503 cites W2082320981 @default.
- W4294012503 cites W2097510503 @default.
- W4294012503 cites W2098124630 @default.
- W4294012503 cites W2103783427 @default.
- W4294012503 cites W2106855201 @default.
- W4294012503 cites W2107277218 @default.
- W4294012503 cites W2118822739 @default.
- W4294012503 cites W2128736149 @default.
- W4294012503 cites W2133520037 @default.
- W4294012503 cites W2138207763 @default.
- W4294012503 cites W2138253007 @default.
- W4294012503 cites W2143282831 @default.
- W4294012503 cites W2152859404 @default.
- W4294012503 cites W2152885121 @default.
- W4294012503 cites W2153533315 @default.
- W4294012503 cites W2162573011 @default.
- W4294012503 cites W2164194503 @default.
- W4294012503 cites W2169456326 @default.
- W4294012503 cites W2179438025 @default.
- W4294012503 cites W2182456467 @default.
- W4294012503 cites W2183393004 @default.
- W4294012503 cites W2192080449 @default.
- W4294012503 cites W2238851414 @default.
- W4294012503 cites W2320030018 @default.
- W4294012503 cites W2339495864 @default.
- W4294012503 cites W2345356016 @default.
- W4294012503 cites W2412937130 @default.
- W4294012503 cites W2432815617 @default.
- W4294012503 cites W2462634178 @default.
- W4294012503 cites W2470481127 @default.
- W4294012503 cites W2529053508 @default.
- W4294012503 cites W2580449060 @default.
- W4294012503 cites W2582602949 @default.
- W4294012503 cites W2584947097 @default.
- W4294012503 cites W2607130335 @default.
- W4294012503 cites W2624262619 @default.
- W4294012503 cites W26395845 @default.
- W4294012503 cites W2704386052 @default.
- W4294012503 cites W2725988230 @default.